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Intr
Severe sepsis is attributable to 37000 deaths per year in
the United Kingdom [1]. Recent studies have suggested
aspirin or statins have a beneficial effect in the treatment
of sepsis, reducing overall mortality [2-4]. This is thought
to be secondary to their anti-inflammatory effect, block-
ing inflammatory cascades triggered in sepsis [2,3].
Objectives
To identify whether aspirin therapy, statin therapy or
combination therapy improves survival in septic patients
admitted to ICU compared to patients receiving neither.
Methods
Patients admitted with sepsis to a 5 bedded teaching
hospital intensive care unit over a 2 year period from
January 2013 to March 2015 were identified utilising the
WardWatcher™ database. Demographic data, outcome
data and medications prescribed during this time were
obtained via the ICU clinical information system, speci-
fically looking for aspirin and statin therapy prior to
admission. This information was subsequently analysed
using an Excel™ spreadsheet.
Results
During the study period, there were a total of 218
(35.7%) admissions to ICU identified with sepsis out of
a total of 611 admissions. Ten were excluded due to
incomplete data. Septic patients were split into four
groups; aspirin therapy, dual aspirin and statin therapy,
statin therapy, neither aspirin nor statin therapy.
The majority (61%) of patients admitted with sepsis
were on neither aspirin nor statin therapy. This patient
group also had the lowest median age of 56. Median
APACHE-II scores were similar in each group and this
was reflected in the lack of any significant survival dif-
ference between groups. Patients on neither therapy
were more likely to survive hospital admission (67.7%)
than those on dual (57.6%) or single aspirin or statin
therapy, although this was not statistically significant.
Conclusions
Our study demonstrates no significant benefit in out-
come from sepsis in intensive care with aspirin or statin
therapy.
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Total number 12 36 33 127
Male:Female ratio 1:1 1:1.25 1:1.2 1:1.1




72 [63-77] 56 [47-68.5]





20 [17-28] 20 [16-26] 20 [14-27]
% Hospital
survival
66.7 63.9 57.6 67.7
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